Cargando…

Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) is a common hematological malignancy. Gemtuzumab ozogamicin (GO), a humanized anti-CD33 antibody conjugated with the potent anti-tumor antibiotic calicheamicin, represents a promising targeted therapy for AML. Annexin A5 (ANXA5) is a proposed marker for the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Nan, Zhang, Ying, Zhang, Ping, Lou, Shifeng, Chen, Ying, Li, Huan, Zeng, Hanqing, Shen, Yan, Deng, Jianchuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310896/
https://www.ncbi.nlm.nih.gov/pubmed/32636939
http://dx.doi.org/10.1177/1758835920927635
_version_ 1783549450907549696
author Zhang, Nan
Zhang, Ying
Zhang, Ping
Lou, Shifeng
Chen, Ying
Li, Huan
Zeng, Hanqing
Shen, Yan
Deng, Jianchuan
author_facet Zhang, Nan
Zhang, Ying
Zhang, Ping
Lou, Shifeng
Chen, Ying
Li, Huan
Zeng, Hanqing
Shen, Yan
Deng, Jianchuan
author_sort Zhang, Nan
collection PubMed
description BACKGROUND: Acute myeloid leukemia (AML) is a common hematological malignancy. Gemtuzumab ozogamicin (GO), a humanized anti-CD33 antibody conjugated with the potent anti-tumor antibiotic calicheamicin, represents a promising targeted therapy for AML. Annexin A5 (ANXA5) is a proposed marker for the clinical prognosis of AML to guide treatment choice. METHODS: In total, 253 patients with pediatric AML were enrolled and divided into two treatment groups: conventional chemotherapy alone and conventional chemotherapy in combination with GO. Univariate, multivariate, and Kaplan–Meier survival analyses were conducted to assess risk factors and clinical outcomes, and to estimate hazard ratios (HRs) and their 95% confidence interval. The level of statistical significance was set at p < 0.05. RESULTS: In the GO treatment group, high ANXA5 expression was considered a favorable prognostic factor for overall survival (OS) and event-free survival (EFS). Multivariate analysis showed that high ANXA5 expression was an independent favorable factor for OS (HR = 0.629, p = 0.084) and EFS (HR = 0.544, p = 0.024) distinct from the curative effect of GO treatment. When all patients were again divided into two groups, this time based on the median expression of ANXA5, patients undergoing chemotherapy combined with GO had significantly better OS (p = 0.0012) and EFS (p = 0.0003) in the ANXA5 high-expression group. Gene set enrichment analysis identified a relevant series of pathways associated with glutathione metabolism, leukocyte transendothelial migration, and hematopoietic cell lineage. CONCLUSION: The expression level of ANXA5 can help optimize the treatment regimen for individual patients, and patients with overexpression of ANXA5 may circumvent poor outcomes from chemotherapy combined with GO.
format Online
Article
Text
id pubmed-7310896
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-73108962020-07-06 Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia Zhang, Nan Zhang, Ying Zhang, Ping Lou, Shifeng Chen, Ying Li, Huan Zeng, Hanqing Shen, Yan Deng, Jianchuan Ther Adv Med Oncol Original Research BACKGROUND: Acute myeloid leukemia (AML) is a common hematological malignancy. Gemtuzumab ozogamicin (GO), a humanized anti-CD33 antibody conjugated with the potent anti-tumor antibiotic calicheamicin, represents a promising targeted therapy for AML. Annexin A5 (ANXA5) is a proposed marker for the clinical prognosis of AML to guide treatment choice. METHODS: In total, 253 patients with pediatric AML were enrolled and divided into two treatment groups: conventional chemotherapy alone and conventional chemotherapy in combination with GO. Univariate, multivariate, and Kaplan–Meier survival analyses were conducted to assess risk factors and clinical outcomes, and to estimate hazard ratios (HRs) and their 95% confidence interval. The level of statistical significance was set at p < 0.05. RESULTS: In the GO treatment group, high ANXA5 expression was considered a favorable prognostic factor for overall survival (OS) and event-free survival (EFS). Multivariate analysis showed that high ANXA5 expression was an independent favorable factor for OS (HR = 0.629, p = 0.084) and EFS (HR = 0.544, p = 0.024) distinct from the curative effect of GO treatment. When all patients were again divided into two groups, this time based on the median expression of ANXA5, patients undergoing chemotherapy combined with GO had significantly better OS (p = 0.0012) and EFS (p = 0.0003) in the ANXA5 high-expression group. Gene set enrichment analysis identified a relevant series of pathways associated with glutathione metabolism, leukocyte transendothelial migration, and hematopoietic cell lineage. CONCLUSION: The expression level of ANXA5 can help optimize the treatment regimen for individual patients, and patients with overexpression of ANXA5 may circumvent poor outcomes from chemotherapy combined with GO. SAGE Publications 2020-05-27 /pmc/articles/PMC7310896/ /pubmed/32636939 http://dx.doi.org/10.1177/1758835920927635 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Zhang, Nan
Zhang, Ying
Zhang, Ping
Lou, Shifeng
Chen, Ying
Li, Huan
Zeng, Hanqing
Shen, Yan
Deng, Jianchuan
Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia
title Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia
title_full Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia
title_fullStr Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia
title_full_unstemmed Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia
title_short Overexpression of annexin A5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia
title_sort overexpression of annexin a5 might guide the gemtuzumab ozogamicin treatment choice in patients with pediatric acute myeloid leukemia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310896/
https://www.ncbi.nlm.nih.gov/pubmed/32636939
http://dx.doi.org/10.1177/1758835920927635
work_keys_str_mv AT zhangnan overexpressionofannexina5mightguidethegemtuzumabozogamicintreatmentchoiceinpatientswithpediatricacutemyeloidleukemia
AT zhangying overexpressionofannexina5mightguidethegemtuzumabozogamicintreatmentchoiceinpatientswithpediatricacutemyeloidleukemia
AT zhangping overexpressionofannexina5mightguidethegemtuzumabozogamicintreatmentchoiceinpatientswithpediatricacutemyeloidleukemia
AT loushifeng overexpressionofannexina5mightguidethegemtuzumabozogamicintreatmentchoiceinpatientswithpediatricacutemyeloidleukemia
AT chenying overexpressionofannexina5mightguidethegemtuzumabozogamicintreatmentchoiceinpatientswithpediatricacutemyeloidleukemia
AT lihuan overexpressionofannexina5mightguidethegemtuzumabozogamicintreatmentchoiceinpatientswithpediatricacutemyeloidleukemia
AT zenghanqing overexpressionofannexina5mightguidethegemtuzumabozogamicintreatmentchoiceinpatientswithpediatricacutemyeloidleukemia
AT shenyan overexpressionofannexina5mightguidethegemtuzumabozogamicintreatmentchoiceinpatientswithpediatricacutemyeloidleukemia
AT dengjianchuan overexpressionofannexina5mightguidethegemtuzumabozogamicintreatmentchoiceinpatientswithpediatricacutemyeloidleukemia